about
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in VietnamFactors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South AfricaUnderstanding pharmacokinetics to improve tuberculosis treatment outcome.Pharmacokinetic interaction of rifapentine and raltegravir in healthy volunteers.Rifabutin Is Active against Mycobacterium abscessus Complex.Pharmacokinetics of rifampin and clarithromycin in patients treated for Mycobacterium ulcerans infection.Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist.Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature.Effect of rifampin and rifabutin on serum itraconazole levels in patients with chronic pulmonary aspergillosis and coexisting nontuberculous mycobacterial infection.Pulmonary aspergilloma: a treatment challenge in sub-Saharan AfricaVirologic outcomes of HAART with concurrent use of cytochrome P450 enzyme-inducing antiepileptics: a retrospective case control study.The ethics of a clinical trial when the protocol clashes with international guidelines.Effect of Rifampin on Thyroid Function Test in Patients on Levothyroxine MedicationEvidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the InternatiRifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report.PXR antagonists and implication in drug metabolism.A physiologically based pharmacokinetic model of rifampin in mice.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Chemotherapeutic interventions against tuberculosisRegulation of microRNA expression by rifampin in human hepatocytes.Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.Factors influencing lopinavir and atazanavir plasma concentration.Rifampin combination therapy for nonmycobacterial infections.Emerging drugs for the treatment of tuberculosis.Antituberculosis drugs: drug interactions, adverse effects, and use in special situations. Part 1: first-line drugs.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.Treatment of prosthetic osteoarticular infections.Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN.Tuberculous pericarditis with and without HIV.Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.The novel antibacterial compound walrycin A induces human PXR transcriptional activityEarly onset of nontuberculous mycobacterial pulmonary disease contributes to the lethal outcome in lung transplant recipients: report of two cases and review of the literature.Drug interaction considerations in the therapeutic use of carbonic anhydrase inhibitors.Rifabutin: where do we stand in 2016?Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat In VitroSimulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Importance of selection and duration of antibiotic regimen in prosthetic joint infections treated with debridement and implant retention.
P2860
Q28538952-CD8F80FF-165C-4AB2-8AB1-24804E210E72Q28546698-76E036C6-1099-43F7-8108-DF8543973048Q30411703-5BA46C2F-2E91-4C79-AD50-34EFCF5A34B4Q33585344-0F905C03-D3D2-4597-885E-62E6B747BAE7Q33726686-D2F8A465-642B-4F8C-9A44-E49A44CEB8E7Q34108761-97DAE1F8-9C8E-4976-AF51-43FD6C94ED2BQ34151106-3A7D29EE-75A0-4EF7-A96D-088B2D21C0CBQ34242199-FCFFED6C-D9B5-488A-BDF5-5DD82CDD8DD7Q34704814-8A3A10D8-F31D-489E-985E-7C7236C9D6E8Q34923083-5D803E0D-52F8-4EF4-9944-1AD990E5A0DEQ35037019-7195783F-9FF7-45B6-A3CB-4E27ABE27D1FQ35057326-295421BB-D623-49EB-A63B-1BCB268ABF30Q35719130-102F29B0-6817-475F-AA6D-B7D796613D21Q36247566-92C07A1A-DA21-4F0E-8D01-8B59D6E57AF3Q36304546-40A04B08-BF82-437E-9D16-77C7F44EE067Q36426845-7AF5DD9B-FEEC-40C5-A5D5-D50E8E5BABD5Q36640752-684D736E-F398-48E3-930E-30FCE998CCA0Q36757635-B3194C54-3E64-4F15-A2E6-45E7BF7805E4Q37113947-6B85A1B2-179F-4C5D-B331-027FFA592B6AQ37148764-B7989292-9D04-4F18-B836-92DBA6BAACA0Q37193112-7C63F97B-AD87-438F-8EAC-A87086B1B055Q37247660-B0057875-E6C9-4718-A60B-24BB6A9457C7Q37476403-BB216F3A-5D74-474F-AF8B-2F627C6B8CBFQ37672039-1EE78020-133B-4F4F-8C47-4CE52E027A8AQ37792105-173136EC-DC7B-44B9-8012-79BB7B09C314Q37810480-691772D2-B21B-449D-A842-16814497AD75Q37826300-4D29A1C0-AE67-4FFB-A901-1819E72E77A0Q37853179-83661FD4-8A63-41FF-8676-6D6A0918AF32Q37973439-A23FDCBF-0772-4C03-B472-36E19167A1C8Q37994619-3564221C-3B8E-4997-8E44-90636C8EA927Q38110140-518E343C-562D-46D6-A648-0F50C4282016Q38207924-1648EA45-9D97-4CA5-B376-70C92C5A0E2FQ38327914-A393D98A-A79D-4C17-AE3A-FBD0D1D34245Q38630117-E68D9BC4-6488-48DE-B388-0D6985B72880Q38733892-00F9E1E4-6909-4213-AAFE-FF89E22F15FFQ38786540-F10E9CD7-8560-4BB9-9F85-1E7A92505473Q38963389-335186EA-3D5F-4FAD-A028-9CB792153E3EQ40162850-AA1BBF9B-F810-4F7B-B5E0-25A0C040A7A7Q40694902-58FA4AE4-1A42-4BBA-AECB-48C847B3F26CQ40772358-34D88F25-FD86-4D83-A4C2-0FD58F34F1B1
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Update on rifampin and rifabutin drug interactions.
@ast
Update on rifampin and rifabutin drug interactions.
@en
Update on rifampin and rifabutin drug interactions.
@nl
type
label
Update on rifampin and rifabutin drug interactions.
@ast
Update on rifampin and rifabutin drug interactions.
@en
Update on rifampin and rifabutin drug interactions.
@nl
prefLabel
Update on rifampin and rifabutin drug interactions.
@ast
Update on rifampin and rifabutin drug interactions.
@en
Update on rifampin and rifabutin drug interactions.
@nl
P2093
P1476
Update on rifampin and rifabutin drug interactions.
@en
P2093
Anne M Baciewicz
Cary R Chrisman
Christopher K Finch
Timothy H Self
P304
P356
10.1097/MAJ.0B013E31814A586A
P407
P577
2008-02-01T00:00:00Z